Q-omics provides the consensus-scored ZNF705D profile across patient tissues and cancer cell-line models. ZNF705D expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ZNF705D is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, ZNF705D RNA expression shows 7,646 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, KIRC, and TGCT as cancer lineages where ZNF705D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF705D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF705D survival associations across molecular data types. ZNF705D RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF705D RNA expression–survival associations across cancer types. High ZNF705D expression shows unfavorable associations in THYM, COAD, UCEC, KIRC, SARC and OV. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify THYM as the clearest survival context for ZNF705D RNA expression.
This table summarizes ZNF705D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF705D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF705D shows higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher ZNF705D RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .041).
This table shows molecular features associated with ZNF705D in patient tissues and cancer cell lines. In patient samples, ZNF705D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF705D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
